Short-term dabigatran cessation induces a rebound prothrombotic state that is attenuated by aspirin

Takeaway

  • Preclinical evidence that short-term cessation of dabigatran, a novel oral anticoagulant (NOAC), induces a rebound prothrombotic state and likely increases the risk of arterial thrombosis; this can potentially be prevented by aspirin pretreatment.

  • NOAC cessation should not be recommended for patients prior to minor surgical procedures with a low risk of bleeding; and if required, should not be discontinued for longer than outlined in the guidelines (i.e. ≤1 or 2 days).

Why this matters

  • A substantial proportion of patients on NOACs cease treatment prior to surgical procedures; evidence suggests that these patients face increased risk of stroke and thromboembolism.

  • It remains unclear if short-term cessation of dabigatran induces a paradoxical rebound prothrombotic state beyond the simple reversal of the anticoagulant effect.

  • These findings will inform clinical decisions regarding NOAC cessation in patients, and the management thereof.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.